On March 3rd, following Altria's official statement ending their investment in American e-cigarette manufacturer Juul, the company announced that they are now free to seek other strategic opportunities and partners to maximize their company's value and advance their leading product technology and innovation pipeline.
Juul has announced that its strategic goal is to help 1 billion adult smokers worldwide quit combustible cigarettes, eliminate their use, and continue to fight against underage use of e-cigarette products. In pursuit of this goal, Juul will continue to seek out new innovative technologies and partnership opportunities to further the company's growth and drive industry transformation.
Although the FDA has issued regulatory orders on certain products by Juul, the company remains confident in its research and evidence and is committed to advancing the process of smoking cessation for adult smokers, promoting public health, and eliminating the threat posed by combustible cigarettes.
Related Reading:
Altria swaps 35% stake for intellectual property, officially announces departure from JUUL.
Reference:
Juul Labs issued a statement regarding Altria's decision to return shares.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
